Abstract
Objectives
The aim of this study was to investigate the expression of Sox2, a transcription factor, in a series of benign, borderline, and malignant ovarian tumors and to evaluate whether Sox2 expression levels correlate with clinicopathological characteristics in ovarian epithelial carcinoma.
Methods
This study investigated immunohistochemical expressions of Sox2 in 43 species of normal ovarian epithelia, 284 species of serous epithelial lesions, and 164 species of mucinous epithelial lesions to assess their clinicopathological relevance.
Results
Immunohistochemical results showed that the positive ratio of Sox2 expression gradually increased from benign and borderline to malignant ovarian tumors; 55.81% of normal ovarian epithelia, ~65% of serous and mucinous cystadenoma, ~70% of borderline serous and mucinous cystadenoma, and ~91% of serous and mucinous cystadenocarcinoma expressed Sox2, respectively. However, there was no significant correlation between Sox2 expression and the age and level of CA125 in patients with either serous or mucinous tumors. Positive correlations between Sox2 expression levels and FIGO stage or pathological stage were identified in both serous and mucinous cystadenocarcinoma samples.
Conclusion
The expression level of Sox2 in human ovarian tumors was directly proportional to their degree of malignancy, implying that Sox2 overexpression may be closely related to the malignant transformation of ovarian tumors.
Abbreviations
- FIGO:
-
International Federation of Gynecology and Obstetrics
- HMG:
-
High mobility group
- IHC:
-
Immunohistochemical
- Sox:
-
SRY-related HMG box
- SRY:
-
Sex-determining region Y
References
Canevari S, Gariboldi M, Reid JF, Bongarzone I, Pierotti MA (2006) Molecular predictors of response and outcome in ovarian cancer. Crit Rev Oncol Hematol 60:19–37
Chobanian N, Dietrich CS III (2008) Ovarian cancer. Surg Clin North Am 88:285–299 vi
Ellis P, Fagan BM, Magness ST, Hutton S, Taranova O, Hayashi S, McMahon A, Rao M, Pevny L (2004) SOX2, a persistent marker for multipotential neural stem cells derived from embryonic stem cells, the embryo or the adult. Dev Neurosci 26:148–165
Gubbay J, Collignon J, Koopman P, Capel B, Economou A, Munsterberg A, Vivian N, Goodfellow P, Lovell-Badge R (1999) A gene mapping to the sex-determining region of the mouse Y chromosome is a member of a novel family of embryonically expressed genes. Nature 346:245–250
Kiernan AE, Pelling AL, Leung KK, Tang AS, Bell DM, Tease C, Lovell-Badge R, Steel KP, Cheah KS (2005) Sox2 is required for sensory organ development in the mammalian inner ear. Nature 434:1031–1035
Li XL, Eishi Y, Bai YQ, Sakai H, Akiyama Y, Tani M, Takizawa T, Koike M, Yuasa Y (2004) Expression of the SRY-related HMG box protein SOX2 in human gastric carcinoma. Int J Oncol 24:257–263
McCluggage WG, Young RH (2005) Immunohistochemistry as a diagnostic aid in the evaluation of ovarian tumors. Semin Diagn Pathol 22:3–32
Park ET, Gum JR, Kakar S, Kwon SW, Deng G, Kim YS (2008) Aberrant expression of SOX2 upregulates MUC5AC gastric foveolar mucin in mucinous cancers of the colorectum and related lesions. Int J Cancer 122:1253–1260
Pevny L, Placzek M (2005) SOX genes and neural progenitor identity. Curr Opin Neurobiol 15:7–13
Rex M, Church R, Tointon K, Ichihashi RM, Mokhtar S, Uwanogho D, Sharpe PT, Scotting PJ (1998) Granule cell development in the cerebellum is punctuated by changes in Sox gene expression. Brain Res Mol Brain Res 55:28–34
Saigusa S, Tanaka K, Toiyama Y, Yokoe T, Okugawa Y, Ioue Y, Miki C, Kusunoki M (2009) Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy. Ann Surg Oncol 16:3488–3498
Sankaranarayanan R, Ferlay J (2006) Worldwide burden of gynaecological cancer: the size of the problem. Best Pract Res Clin Obstet Gynaecol 20:207–225
Santagata S, Ligon KL, Hornick JL (2007) Embryonic stem cell transcription factor signatures in the diagnosis of primary and metastatic germ cell tumors. Am J Surg Pathol 31:836–845
Schepers GE, Teasdale RD, Koopman P (2002) Twenty pairs of sox: extent, homology, and nomenclature of the mouse and human sox transcription factor gene families. Dev Cell 3:167–170
Sholl LM, Long KB, Hornick JL (2009) Sox2 expression in pulmonary non-small cell and neuroendocrine carcinomas. Appl Immunohistochem Mol Morphol 18:55
Sinclair AH, Berta P, Palmer MS, Hawkins JR, Griffiths BL, Smith MJ, Foster JW, Frischauf AM, Lovell-Badge R, Goodfellow PN (1990) A gene from the human sex-determining region encodes a protein with homology to a conserved DNA-binding motif. Nature 346:240–244
Swart AM, Burdett S, Ledermann J, Mook P, Parmar MK (2008) Why i.p. therapy cannot yet be considered as a standard of care for the first-line treatment of ovarian cancer: a systematic review. Ann Oncol 19:688–695
Taranova OV, Magness ST, Fagan BM, Wu Y, Surzenko N, Hutton SR, Pevny LH (2006) SOX2 is a dose-dependent regulator of retinal neural progenitor competence. Genes Dev 20:1187–1202
van der Burg ME (2001) Advanced ovarian cancer. Curr Treat Options Oncol 2:109–118
Vang R, Shih I, Kurman RJ (2009) Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol 16:267–282
Wegner M (1999) From head to toes: the multiple facets of Sox proteins. Nucl Acids Res 27:1409–1420
Acknowledgments
Our research was supported by the Chinese National Natural Science Foundation 30973380 and the Foundation of Health Bureau of Zhejiang Province, China (2007A129, 2008A110), Young Talent Foundation of Health Bureau of Zhejiang Province, China (2007QN010).
Conflict of interest statement
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ye, F., Li, Y., Hu, Y. et al. Expression of Sox2 in human ovarian epithelial carcinoma. J Cancer Res Clin Oncol 137, 131–137 (2011). https://doi.org/10.1007/s00432-010-0867-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-010-0867-y